-
EP3773527
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3773527
| EP3773527 - METHOD AND COMPOSITION FOR TREATING CNS DISORDERS [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 27.06.2024 Database last updated on 02.11.2024 | |
| Former | Request for examination was made Status updated on 15.01.2021 | ||
| Former | The international publication has been made Status updated on 05.10.2019 | Most recent event Tooltip | 25.10.2024 | Change: Despatch of examination report + time limit | Applicant(s) | For all designated states IGC PHARMA IP, LLC 10224 Falls Road Potomac, MD 20854 / US | [2024/08] |
| Former [2021/07] | For all designated states India Globalization Capital, Inc. 10224 Falls Road Potomac, MD 20854 / US | Inventor(s) | 01 /
MUKUNDA, Ramachandra 8909 Tuckerman Lane Potomac, MD 20854 / US | 02 /
RAO, Jagadeesh S. 20104 Boxwood Place Ashburn, VA 20147 / US | 03 /
MUKUNDA, Amar R. 7420 West Lake Terrace Apt. 108 Bethesda, MD 20817 / US | [2021/07] | Representative(s) | Script Intellectual Property LLP Suite J, Anchor House School Close Chandlers Ford Eastleigh, Hampshire SO53 4DY / GB | [N/P] |
| Former [2021/07] | McQueen, Andrew Peter Miltons IP - Europe 5th Floor, Broad Quay House Prince Street Bristol BS1 4DJ / GB | Application number, filing date | 19777467.2 | 29.03.2019 | [2021/07] | WO2019US00014 | Priority number, date | US201862650942P | 30.03.2018 Original published format: US 201862650942 P | [2021/07] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019190608 | Date: | 03.10.2019 | Language: | EN | [2019/40] | Type: | A1 Application with search report | No.: | EP3773527 | Date: | 17.02.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 03.10.2019 takes the place of the publication of the European patent application. | [2021/07] | Search report(s) | International search report - published on: | US | 03.10.2019 | (Supplementary) European search report - dispatched on: | EP | 15.03.2022 | Classification | IPC: | A61K31/05, A61K31/137, A61K31/4045, A61K31/12, A61K31/352, A61K31/7048, A61K36/185, A61K36/9066, A61K47/26, A61K45/06, A61P25/00, A61P25/16, A61P25/28, A61K9/00, A61K9/10 | [2022/15] | CPC: |
A61P25/16 (EP);
A61K31/4045 (EP,US);
A61K31/05 (EP,US);
A61K31/12 (EP,US);
A61K31/192 (US);
A61K31/352 (EP,US);
A61K31/7048 (EP,US);
A61K36/185 (EP);
A61K36/9066 (EP);
A61K45/06 (EP);
A61K47/26 (EP);
A61K9/0095 (EP);
A61K9/10 (EP);
A61P25/00 (EP);
A61P25/28 (EP);
A61K9/107 (US)
(-)
| C-Set: |
A61K31/05, A61K2300/00 (EP);
A61K31/12, A61K2300/00 (EP);
A61K31/352, A61K2300/00 (EP);
A61K31/4045, A61K2300/00 (EP);
A61K31/7048, A61K2300/00 (EP);
A61K36/185, A61K2300/00 (EP); |
| Former IPC [2021/07] | A61K31/05, A61K31/137, A61K31/4045 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/07] | Title | German: | VERFAHREN UND ZUSAMMENSETZUNG ZUR BEHANDLUNG VON ZNS-ERKRANKUNGEN | [2021/07] | English: | METHOD AND COMPOSITION FOR TREATING CNS DISORDERS | [2021/07] | French: | MÉTHODE ET COMPOSITION DE TRAITEMENT DE TROUBLES DU SNC | [2021/07] | Entry into regional phase | 28.10.2020 | National basic fee paid | 28.10.2020 | Search fee paid | 28.10.2020 | Designation fee(s) paid | 28.10.2020 | Examination fee paid | Examination procedure | 28.10.2020 | Examination requested [2021/07] | 21.11.2022 | Amendment by applicant (claims and/or description) | 27.06.2024 | Despatch of a communication from the examining division (Time limit: M06) | Fees paid | Renewal fee | 06.08.2021 | Renewal fee patent year 03 | 30.03.2022 | Renewal fee patent year 04 | 20.03.2023 | Renewal fee patent year 05 | 26.03.2024 | Renewal fee patent year 06 | Penalty fee | Additional fee for renewal fee | 31.03.2021 | 03 M06 Fee paid on 06.08.2021 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I]GB2434312 (GW PHARMA LTD [GB]); | [I]WO2010045577 (HERBALSCIENCE GROUP LLC [US], et al); | International search | [XY]US2007049576 (BARLOW CARROLEE [US], et al) [X] 1-8, 11-12, 15-19 * ; para [0009]-[0010], [0060], [0062], [0104], [0116], [0148], [0151]-[0152], [0217], [0284], [0290], [0297]-[0299] * [Y] 9-10, 13-14; | [A]US2008033027 (BASCOMB NEWELL [US], et al) [A] 1-19* ; see entire document *; | [A]US2011257256 (FUCHS DIETMAR [AT], et al) [A] 1-19 * ; see entire document *; | [Y]US2016081927 (BROMLEY PHILIP J [US]) [Y] 9-10, 13-14 * ; para [0022], [0077], [0305], [0310], [0319], [0383] * | by applicant | US2007049576 | GB2434312 | US2008033027 | WO2010045577 | US2011257256 | US2016081927 | - "2012 Alzheimer's disease facts and figures", Alzheimer Dement, (20120000), vol. 8, pages 131 - 168 | - ; BROOKMEYER et al., "Forecasting the global burden of Alzheimer's disease", Alzheimer Dement, (20070000), vol. 3, doi:10.1016/j.jalz.2007.04.381, pages 186 - 191, XP022100576 DOI: http://dx.doi.org/10.1016/j.jalz.2007.04.381 | - SCHITT et al., CNS Drugs, (20040000), vol. 18, pages 827 - 844 | - SAXENA, "Bioenergetics breakdown in Alzheimer's disease: Targets for new therapies", Int J Physiol Pathophysiol Pharmacol., (20110000), vol. 3, pages 133 - 139 | - GOTZ et al., "Modes of Ap toxicity in Alzheimer's disease", Cell Mol Life Sci., (20110000), vol. 68, doi:10.1007/s00018-011-0750-2, pages 3359 - 3375, XP019957649 DOI: http://dx.doi.org/10.1007/s00018-011-0750-2 | - CHITIDOBSON, "Protein misfolding, functional amyloid, and human disease", Annu Rev Biochem., (20060000), vol. 75, doi:10.1146/ANNUREV.BIOCHEM.75.101304.123901, pages 333 - 366, XP002534902 DOI: http://dx.doi.org/10.1146/ANNUREV.BIOCHEM.75.101304.123901 | - CAMPBELLGOWRAN, "Alzheimer's disease; taking the edge off with cannabinoids?", Br J Pharmacol., (20070000), vol. 152, doi:10.1038/sj.bjp.0707446, pages 655 - 662, XP071093517 DOI: http://dx.doi.org/10.1038/sj.bjp.0707446 | - RICH et al., "Nonsteroidal anti-inflammatory drugs in Alzheimer's disease", Neurology, (19950000), vol. 45, pages 51 - 55, XP002070243 | - OCTAVE, "The amyloid peptide and its precursor in Alzheimer's disease", Rev Neurosci., (19950000), vol. 6, pages 287 - 316 | - REITZ et al., "Epidemiology of Alzheimer disease", Nat Rev Neural., (20110000), vol. 7, pages 137 - 152 | - PILLAY et al., "Molecular mechanisms, emerging etiological insights and models to test potential therapeutic interventions in Alzheimer's disease", Curr Alzheimer Res, (20040000), vol. 1, pages 295 - 306 | - HOOPER et al., "The GSK3 hypothesis of Alzheimer's disease", J Neurochem., (20080000), vol. 104, pages 1433 - 1439 | - PROCTORGRAY, "GSK3 and p53 - is there a link in Alzheimer's disease?", Mol Neurodegener, (20100000), vol. 5, page 7 | - LOVESTONE et al., "Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells", Curr Biol., (19940000), vol. 4, doi:10.1016/S0960-9822(00)00246-3, pages 1077 - 1086, XP024248920 DOI: http://dx.doi.org/10.1016/S0960-9822(00)00246-3 | - ISHIGURO et al., "Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments", Neurosci Lett., (19920000), vol. 148, doi:10.1016/0304-3940(92)90839-Y, pages 202 - 206, XP025445875 DOI: http://dx.doi.org/10.1016/0304-3940(92)90839-Y | - HANGER et al., "Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localization of the kinase", Neurosci Lett., (19920000), vol. 147, pages 58 - 62 | - CHOJOHNSON, "Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding", J Biol Chem., (20030000), vol. 278, pages 187 - 193 | - ASUNI et al., "GSK3alpha exhibits beta-catenin and tau directed kinase activities that are modulated by Wnt", Eur J Neurosci., (20060000), vol. 24, pages 3387 - 3392 | - HERNANDEZ et al., "GSK3 and tau: Two convergence points in Alzheimer's disease", J Alzheimers Dis., (20130000), vol. 33, pages S141 - S144 | - ENGEL et al., "Chronic lithium administration to FTDP-17 tau and GSK- 3beta over expressing mice checks tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert", J Neurochem., (20060000), vol. 99, pages 1445 - 1455 | - PHIEL et al., "GSK-3alpha controls production of Alzheimer's disease amyloid-beta peptides", Nature, (20030000), vol. 423, doi:10.1038/nature01640, pages 435 - 439, XP008161488 DOI: http://dx.doi.org/10.1038/nature01640 | - SUN et al., "Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100", Neurosci Lett, (20020000), vol. 321, pages 61 - 64 | - DAROCHA-SOUTO et al., "Activation of glycogen synthase kinase-3 beta mediates beta-amyloid induced neuritic damage in Alzheimer's disease", Neurobiol Dis, (20120000), vol. 45, doi:10.1016/j.nbd.2011.09.002, pages 425 - 437, XP028598897 DOI: http://dx.doi.org/10.1016/j.nbd.2011.09.002 | - JACKSON et al., "Cannabinoids and neuroprotection in CNS inflammatory disease", J Neurol Sci, (20050000), vol. 233, doi:10.1016/j.jns.2005.03.002, pages 21 - 25, XP004932275 DOI: http://dx.doi.org/10.1016/j.jns.2005.03.002 | - CAMPBELLGOWRAN, "Alzheimer's disease; taking the edge off with cannabinoids?", Br J Pharmacol, (20070000), vol. 152, doi:10.1038/sj.bjp.0707446, pages 655 - 662, XP071093517 DOI: http://dx.doi.org/10.1038/sj.bjp.0707446 | - RIEDELDAVIES, "Cannabinoid function in learning, memory and plasticity", Handb Exp Pharmacol, (20050000), pages 445 - 477 | - VAN SICKLE et al., "Identification and functional characterization of brainstem cannabinoid CB2 receptors", Science, (20050000), vol. 310, pages 329 - 332 | - ASHTON et al., "Expression of the cannabinoid CB2 receptor in the rat cerebellum: An immunohistochemical study", Neurosci Lett, (20060000), vol. 396, doi:10.1016/j.neulet.2005.11.038, pages 113 - 116, XP025023580 DOI: http://dx.doi.org/10.1016/j.neulet.2005.11.038 | - NUNEZ et al., "Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: An immunohistochemical study", Synapse, (20040000), vol. 53, pages 208 - 213 | - MARCHALANT et al., "Cannabinoids attenuate the effects of aging upon neuroinflammation and neurogenesis", Neurobiol Dis., (20090000), vol. 34, doi:10.1016/j.nbd.2009.01.014, pages 300 - 307, XP026052963 DOI: http://dx.doi.org/10.1016/j.nbd.2009.01.014 | - RAMIREZ et al., "Prevention of Alzheimer's disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation", J Neurosci., (20050000), vol. 25, doi:10.1523/JNEUROSCI.4540-04.2005, pages 1904 - 1913, XP055258274 DOI: http://dx.doi.org/10.1523/JNEUROSCI.4540-04.2005 | - BENITO et al., "Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains", J Neurosci., (20030000), vol. 23, pages 11136 - 11141 | - MARTIN-MORENO et al., "Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: Relevance to Alzheimer's disease", Mol Pharmacol., (20110000), vol. 79, pages 964 - 973 | - BISOGNODI MARZO, "Cannabinoid receptors and endocannabinoids: Role in neuroinflammatory and neurodegenerative disorders", CNS Neurol Disord Drug Targets., (20100000), vol. 9, pages 564 - 573 | - PIOMELLI, "The molecular logic of endocannabinoid signaling", Nat Rev Neurosci., (20030000), vol. 4, pages 873 - 884 | - VOLICER et al., "Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease", Int J Geriatr Psychiatry., (19970000), vol. 12, pages 913 - 919 | - JACKSON et al., "Cannabinoids and neuroprotection in CNS inflammatory disease", J Neurol Sci., (20050000), vol. 233, doi:10.1016/j.jns.2005.03.002, pages 21 - 25, XP004932275 DOI: http://dx.doi.org/10.1016/j.jns.2005.03.002 | - FISHBEIN et al., "Long-term behavioral and biochemical effects of an ultra-low dose of Δ9-tetrahydrocannabinol (THC): neuroprotection and ERK signaling", Exp Brain Res., (20120000), vol. 221, doi:10.1007/s00221-012-3186-5, pages 437 - 448, XP035103539 DOI: http://dx.doi.org/10.1007/s00221-012-3186-5 | - EUBANKS LMROGERS CJBEUSCHER AE 4KOOB GFOLSON AJDICKERSON TJJANDA KD, "A molecular link between the active component of marijuana and Alzheimer's disease pathology", Mol Pharm., (20061100), vol. 3, no. 6, pages 773 - 7 | - "The human pineal gland and melatonin in aging and Alzheimer's disease", J. Pineal Res., (20050000), vol. 38, pages 145 - 152 | - WU YH.FEENSTRA M.G.ZHOU J.N.LIU R.Y.TORANO J.S.VAN KAN H.J.FISCHER D.F.RAVID R.SWAAB D.F, "Molecular changes underlying reduced pineal melatonin levels in Alzheimer's disease: Alterations in preclinical and clinical stages", J. Clin. Endocr. Metab., (20030000), vol. 88, pages 5898 - 5906 | - COHEN-MANSFIELD J.GARFINKEL D.LIPSON S, "Melatonin for treatment of sundowning in elderly persons with dementia—A preliminary study", Arch. Gerontol. Geriatr., (20000000), vol. 31, pages 65 - 76 | - CARDINALI D.P.BRUSCO L.I.PEREZ LLORET S.FURIO A.M, "Melatonin in sleep disorders and jet-lag", Neuro Endocrinol. Lett, (20020000), vol. 23, pages 9 - 13, XP008025315 | - KARASEK M.REITER R.J.CARDINALI D.P.PAWLIKOWSKI M, "Future of melatonin as a therapeutic agent", Neuro Endocrinol. Lett., (20020000), vol. 23, pages 118 - 121 | - SINGER C.TRACTENBERG R.E.KAYE J.SCHAFER K.GAMST A.GRUNDMAN M.THOMAS R.THAI L.J, "Alzheimer's disease cooperative, SA multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease", Sleep, (20030000), vol. 26, pages 893 - 901 | - NORDLUND JJLERNER AB, "The effects of oral melatonin on skin color and on the release of pituitary hormones", J Clin Endocrinol Metab., (19770000), vol. 45, pages 768 - 774 | - PAPVASILIOU PSCOTZIAS GCDUBY SESTECK AJBELL MLAWRENCE WH, "Melatonin and parkinsonism", JAMA, (19720000), vol. 221, page 88 | - GOEL AKUNNUMAKKARA ABAGGARWAL BB, "Curcumin as ''Curecumin'': from kitchen to clinic", Biochem Pharmacol., (20080215), vol. 75, no. 4, doi:10.1016/j.bcp.2007.08.016, pages 787 - 809, XP025743546 DOI: http://dx.doi.org/10.1016/j.bcp.2007.08.016 | - MAITI PDUNBAR GL, "Use of Curcumin, a Natural Polyphenol for Targeting Molecular Pathways in Treating Age-Related Neurodegenerative Diseases", Int J Mol Sci., (20180531), vol. 19, no. 6 | - KORONYO- HAMAOUI MKORONYO YLJUBIMOV AVMILLER CAKO MKBLACK KLSCHWARTZ MFARKAS DL, "Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model", Neuroimage, (20110100), vol. 54, pages S204 - 17, XP027581784 | - MAITI PHALL TCPALADUGU LKOLLI NLEARMAN CROSSIGNOL JDUNBAR GL, "A comparative study of dietary curcumin, nanocurcumin, and other classical amyloid-binding dyes for labeling and imaging of amyloid plaques in brain tissue of 5x-familial Alzheimer's disease mice", Histochem Cell Biol., (20161100), vol. 146, no. 5, doi:10.1007/s00418-016-1464-1, pages 609 - 625, XP036081355 DOI: http://dx.doi.org/10.1007/s00418-016-1464-1 | - MAITI PPALADUGU LDUNBAR GL, "Solid lipid curcumin particles provide greater anti-amyloid, anti-inflammatory and neuroprotective effects than curcumin in the 5xFAD mouse model of Alzheimer's disease", BMC Neurosci, (20180223), vol. 19, no. 1, page 7 | - MOHORKO NREPOVS GPOPOVIC MKOVACS GGBRESJANAC M, "Curcumin labeling of neuronal fibrillar tau inclusions in human brain samples", J Neuropathol Exp Neurol., (20100400), vol. 69, no. 4, pages 405 - 14 | - MUTSUGA MCHAMBERS JKUCHIDA KTEI MMAKIBUCHI TMIZOROGI TTAKASHIMA ANAKAYAMA H, "Binding of curcumin to senile plaques and cerebral amyloid angiopathy in the aged brain of various animals and to neurofibrillary tangles in Alzheimer's brain", J Vet Med Sci., (20120100), vol. 74, no. 1, pages 51 - 7 | - MISHRA SMISHRA MSETH PSHARMA SK, "Tetrahydrocurcumin confers protection against amyloid 0-induced toxicity", Neuroreport, (20110105), vol. 22, no. 1, pages 23 - 7 | - SMALL et al., "Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial", Am J Geriatr Psychiatry, (20180300), vol. 26, no. 3, pages 266 - 277 | - LAO C.D.RUFFIN M.T.NORMOLLE D.HEATH D.D.MURRAY S.I.BAILEY J.M.BOGGS M.E.CROWELL J.ROCK C.L.BRENNER D.E, "Dose escalation of a curcuminoid formulation. BMC Complement", Altern. Med., (20060000), vol. 6, page 10 |